SCHEDULE 1 CONTROLLED DRUGS SUBJECT TO THE REQUIREMENTS OF REGULATIONS 14, 15, 16, 18, 19, 20, 23, 26 AND 27

Regulation 3

1

The following substances and products, namely -

a

Bufotenine

  • Cannabinol

  • Cannabinol derivatives not being dronabinol or its stereoisomers

  • Cannabis and cannabis resin

  • Cathinone

  • Coca leaf

  • Concentrate of poppy-straw

  • F2[2,3–Dihydro–5–methyl–3–(4–morpholinylmethyl)pyrrolo[1, 2, 3–de]–1,4–benzoxazin–6–yl]–1–naphthalenylmethanone

  • F23–Dimethylheptyl–11–hydroxyhexahydrocannabinol

  • Eticyclidine

  • Etryptamine

  • F1Fungus (of any kind) which contains psilocin or an ester of psilocin

  • F3[9–Hydroxy–6–methyl–3–[5–phenylpentan–2–yl] oxy–5, 6, 6a, 7, 8, 9, 10, 10a–octahydrophenanthridin–1–yl] acetate

  • F39-(Hydroxymethyl)–6, 6–dimethyl–3–(2–methyloctan–2–yl)–6a, 7, 10, 10a–tetrahydrobenzo[c]chromen–1–ol

  • Lysergamide

  • Lysergide and otherN-alkyl derivatives of lysergamide

  • Mescaline

  • Methcathinone

  • F7...

  • Psilocin

  • Raw opium

  • Rolicyclidine

  • Tenocyclidine

  • 4-Bromo-2,5-dimethoxy-a-methylphenethylamine

  • N,N-Diethyltryptamine

  • N,N-Dimethyltryptamine

  • 2,5-Dimethoxy-a,4-dimethylphenethylamine

  • N-Hydroxy-tenamphetamine

  • 4-Methyl-aminorex

b

any compound (not being a compound for the time being specified in sub-paragraph (a) above) structurally derived from tryptamine or from a ring-hydroxy tryptamine by substitution at the nitrogen atom of the sidechain with one or more alkyl substituents but no other substituent;

c

the following phenethylamine derivatives, namely—

  • Allyl(a-methyl-3,4-methylenedioxyphenethyl)amine

  • 2-Amino-1-(2,5-dimethoxy-4-methylphenyl)ethanol

  • 2-Amino-1-(3,4-dimethoxyphenyl)ethanol

  • Benzyl(a-methyl-3,4-methylenedioxyphenethyl)amine

  • 4-Bromo-b,2,5-trimethoxyphenethylamine

  • N-(4-sec-Butylthio-2,5-dimethoxyphenethyl)hydroxylamine

  • Cyclopropylmethyl(a-methyl-3,4-methylenedioxyphenethyl)amine

  • 2-(4,7-Dimethoxy-2,3-dihydro-1H-indan-5-yl)ethylamine

  • 2-(4,7-Dimethoxy-2,3-dihydro-1H-indan-5-yl)-1-methylethylamine

  • 2-(2,5-Dimethoxy-4-methylphenyl)cyclopropylamine

  • 2-(1,4-Dimethoxy-2-naphthyl)ethylamine

  • 2-(1,4-Dimethoxy-2-naphthyl)-1-methylethylamine

  • N-(2,5-Dimethoxy-4-propylthiophenethyl)hydroxylamine

  • 2-(1,4-Dimethoxy-5,6,7,8-tetrahydro-2-naphthyl)ethylamine

  • 2-(1,4-Dimethoxy-5,6,7,8-tetrahydro-2-naphthyl)-1-methylethylamine

  • a,a-Dimethyl-3,4-methylenedioxyphenethylamine

  • a,a-Dimethyl-3,4-methylenedioxyphenethyl(methyl)amine

  • Dimethyl(a-methyl-3,4-methylenedioxyphenethyl)amine

  • N-(4-Ethylthio-2,5-dimethoxyphenethyl)hydroxylamine

  • 4-Iodo-2,5-dimethoxy-a-methylphenethyl(dimethyl)amine

  • 2-(1,4-Methano-5,8-dimethoxy-1,2,3,4-tetrahydro-6-naphthyl)ethylamine

  • 2-(1,4-Methano-5,8-dimethoxy-1,2,3,4-tetrahydro-6-naphthyl)-1-methylethylamine

  • 2-(5-Methoxy-2,2-dimethyl-2,3-dihydrobenzo[b]furan-6-yl)-1-methylethylamine

  • 2-Methoxyethyl(a-methyl-3,4-methylenedioxyphenethyl)amine

  • 2-(5-Methoxy-2-methyl-2,3-dihydrobenzo[b]furan-6-yl)-1-methylethylamine

  • b-Methoxy-3,4-methylenedioxyphenethylamine

  • 1-(3,4-Methylenedioxybenzyl)butyl(ethyl)amine

  • 1-(3,4-Methylenedioxybenzyl)butyl(methyl)amine

  • 2-(a-Methyl-3,4-methylenedioxyphenethylamino)ethanol

  • a-Methyl-3,4-methylenedioxyphenethyl(prop-2-ynyl)amine

  • N-Methyl-N-(a-methyl-3,4-methylenedioxyphenethyl)hydroxylamine

  • O-Methyl-N-(a-methyl-3,4-methylenedioxyphenethyl)hydroxylamine

  • a-Methyl-4-(methylthio)phenethylamine

  • b,3,4,5-Tetramethoxyphenethylamine

  • b,2,5-Trimethoxy-4-methylphenethylamine

d

any compound (not being methoxyphenamine or a compound for the time being specified in sub-paragraph (a) above) structurally derived from phenethylamine, anN-alkylphenethylamine,a-methylphenethylamine, anN-alkyl-a-methylphenethylamine,a-ethylphenethylamine, or anN-alkyl-a-ethylphenethylamine by substitution in the ring to any extent with alkyl, alkoxy, alkylenedioxy or halide substitutents, whether or not further substituted in the ring by one or more other univalent substituents;

e

any compound (not being a compound for the time being specified in Schedule 2) structurally derived from fentanyl by modification in any of the following ways, that is to say -

i

by replacement of the phenyl portion of the phenethyl group by any heteromonocycle whether or not further substituted in the heterocycle;

ii

by substitution in the phenethyl group with alkyl, alkenyl, alkoxy, hydroxy, halogeno, haloalkyl, amino or nitro groups;

iii

by substitution in the piperidine ring with alkyl or alkenyl groups;

iv

by substitution in the aniline ring with alkyl, alkoxy, alkylenedioxy, halogeno or haloalkyl groups;

v

by substitution at the 4-position of the piperidine ring with any alkoxycarbonyl or alkoxyalkyl or acyloxy group;

vi

by replacement of theN-propionyl group by another acyl group;

f

any compound (not being a compound for the time being specified in Schedule 2) structurally derived from pethidine by modification in any of the following ways, that is to say—

i

by replacement of the l-methyl group by an acyl, alkyl whether or not unsaturated, benzyl or phenethyl group, whether or not further substituted;

ii

by substitution in the piperidine ring with alkyl or alkenyl groups or with a propano bridge, whether or not further substituted;

iii

by substitution in the 4-phenyl ring with alkyl, alkoxy, aryloxy, halogeno or haloalkyl groups;

iv

by replacement of the 4-ethoxycarbonyl by any other alkoxycarbonyl or any alkoxyalkyl or acyloxy group;

v

by formation of an N-oxide or of a quaternary base.

F4g

1–benzylpiperazine or any compound (not being a compound for the time being specified in Schedule 4) structurally derived from 1–benzylpiperazine or 1–phenylpiperazine by modification in any of the following ways—

i

by substitution at the second nitrogen atom of the piperazine ring with alkyl, benzyl, haloalkyl or phenyl groups;

ii

by substitution in the aromatic ring to any extent with alkyl, alkoxy, alkylenedioxy, halide or haloalkyl groups;

h

any compound structurally derived from 3–(1–naphthoyl)indole or 1H–indol–3–yl–(1–naphthyl)methane by substitution at the nitrogen atom of the indole ring by alkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl or 2–(4–morpholinyl)ethyl, whether or not further substituted in the indole ring to any extent and whether or not substituted in the naphthyl ring to any extent;

i

any compound structurally derived from 3–(1–naphthoyl)pyrrole by substitution at the nitrogen atom of the pyrrole ring by alkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl or 2–(4–morpholinyl)ethyl, whether or not further substituted in the pyrrole ring to any extent and whether or not substituted in the naphthyl ring to any extent;

j

any compound structurally derived from 1–(1–naphthylmethyl)indene by substitution at the 3–position of the indene ring by alkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl or 2–(4–morpholinyl)ethyl, whether or not further substituted in the indene ring to any extent and whether or not substituted in the naphthyl ring to any extent;

k

any compound structurally derived from 3–phenylacetylindole by substitution at the nitrogen atom of the indole ring with alkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl or 2–(4–morpholinyl)ethyl, whether or not further substituted in the indole ring to any extent and whether or not substituted in the phenyl ring to any extent;

l

any compound structurally derived from 2–(3–hydroxycyclohexyl)phenol by substitution at the 5–position of the phenolic ring by alkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl or 2–(4–morpholinyl)ethyl, whether or not further substituted in the cyclohexyl ring to any extent.

F5m

Any compound (not being bupropion, diethylpropion, pyrovalerone or a compound for the time being specified in sub–paragraph (a) above) structurally derived from 2–amino–1–phenyl–1–propanone by modification in any of the following ways, that is to say—

i

by substitution in the phenyl ring to any extent with alkyl, alkoxy, alkylenedioxy, haloalkyl or halide substituents, whether or not further substituted in the phenyl ring by one or more other univalent substituents;

ii

by substitution at the 3–position with an alkyl substituent;

iii

by substitution at the nitrogen atom with alkyl or dialkyl groups, or by inclusion of the nitrogen atom in a cyclic structure.

F6n

Any compound structurally derived from 2–aminopropan–1–one by substitution at the 1‑position with any monocyclic, or fused‑polycyclic ring system (not being a phenyl ring or alkylenedioxyphenyl ring system), whether or not the compound is further modified in any of the following ways, that is to say—

i

by substitution in the ring system to any extent with alkyl, alkoxy, haloalkyl or halide substituents, whether or not further substituted in the ring system by one or more other univalent substituents;

ii

by substitution at the 3–position with an alkyl substituent;

iii

by substitution at the 2‑amino nitrogen atom with alkyl or dialkyl groups, or by inclusion of the 2‑amino nitrogen atom in a cyclic structure.

2

Any stereoisomeric form of a substance specified in paragraph 1.

3

Any ester or ether of a substance specified in paragraph 1 or 2.

4

Any salt of a substance specified in any of paragraphs 1 to 3.

5

Any preparation or other product containing a substance or product specified in any of paragraphs 1 to 4, not being a preparation specified in Schedule 5.